Skip to main content

Advertisement

SpringerLink
Log in

Cancer therapy

Boosting CAR T cells with anti-tumor mRNA vaccines

  • News & Views
  • Published:

From Nature Medicine

View current issue Submit your manuscript

A new approach that combines CAR T cells with serial mRNA vaccine injections facilitates robust anti-neoplastic activity in patients with genitourinary cancers, which will pave the way for a promising new targeted treatment strategy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1: CAR T cell–CARVac therapy in CLDN6+ solid tumors.

References

  1. June, C. H. & Sadelain, M. N. Engl. J. Med. 379, 64–73 (2018).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Sterner, R. C. & Sterner, R. M. Blood Cancer J 11, 1–11 (2021).

    Article  Google Scholar 

  3. Mackensen, A. et al. Nat. Med. https://doi.org/10.1038/s41591-023-02612-0 (2023).

    Article  PubMed  Google Scholar 

  4. Hewitt, K. J., Agarwal, R. & Morin, P. J. BMC Cancer 6, 186 (2006).

    Article  PubMed  PubMed Central  Google Scholar 

  5. Zhang, C. et al. Front. Cell Dev. Biol. 9, 726656 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ushiku, T., Shinozaki-Ushiku, A., Maeda, D., Morita, S. & Fukayama, M. Histopathology 61, 1043–1056 (2012).

    Article  PubMed  Google Scholar 

  7. Veenstra, C. M. & Vaughn, D. J. Hematol. Oncol. Clin. North Am. 25, 577–591 (2011).

    Article  PubMed  Google Scholar 

  8. Mateus-Tique, J. & Brown, B. Nat. Rev. Immunol. 23, 7 (2023).

    Article  CAS  PubMed  Google Scholar 

  9. Kranz, L. M. et al. Nature 534, 396–401 (2016).

    Article  PubMed  Google Scholar 

  10. Reinhard, K. et al. Science 367, 446–453 (2020).

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medical Oncology & Experimental Therapeutics; City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Alex Chehrazi-Raffle & Sumanta K. Pal

  2. Department of Hematology & Hematopoietic Cell Transplantation; City of Hope Comprehensive Cancer Center, Duarte, CA, USA

    Lihua E. Budde

Authors
  1. Alex Chehrazi-Raffle
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lihua E. Budde
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sumanta K. Pal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sumanta K. Pal.

Ethics declarations

Competing interests

A.C.-R. reports consulting roles with Aveo, Exelixis and Tempus Labs. S.K.P. reports consulting roles in Genentech, Aveo, Eisai, Roche, Pfizer, Novartis, Exelixis, Ipsen, BMS and Astellas. L.E.B. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Chehrazi-Raffle, A., Budde, L.E. & Pal, S.K. Boosting CAR T cells with anti-tumor mRNA vaccines. Nat Med 29, 2711–2712 (2023). https://doi.org/10.1038/s41591-023-02623-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41591-023-02623-x

  • Springer Nature America, Inc.

Search

Navigation